News & Publications

A study with the longest follow-up of immunotherapy as the first line treatment for patients with advanced MCC has showed improved overall survival and response rate compared to controls. The study included 50 treatment naïve adults with advanced MCC who received a median of 10.5 doses of pembroliz...

This study analyzed outcomes from the care of 8252 Merkel cell carcinoma patients at 1147 facilities in the US. It found that patients did better if cared for at higher volume / larger facilities. Such facilities tend to follow evidence-based guidelines, and are more likely to provide multi-discipli...

3 generations of mentor-mentees gathered in Aomori Japan at the Japanese Society for Investigative Dermatology. DOM members Drs Masaoki Kawasumi, Tomoko Akaike, and Paul Nghiem, all gave plenary session talks. Left to right: Tomoko Akaike is a Japanese dermatologist doing a clinical research ...

Parents are always looking out for their kids. It’s rare when it happens the other way around. But Susan Manber’s 13-year-old daughter saved her life. It happened one afternoon, not long after Hurricane Sandy had wreaked havoc on the New York City area. “We’d been without power for two weeks...

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circ...

On September 9, 2019 in Seattle, over 280 patients, family members, clinicians, scientists, pharmaceutical partners, and trainees from across the United States gathered for the 14th annual Merkel cell carcinoma Dinner Meeting. The evening began with a bit of social gathering, beautiful music (vio...

Living with Merkel Cell Carcinoma is a free workshop series organized by CancerCare and can be attended over the phone or online. Part I of the series, Treatment Perspectives on Merkel Cell Carcinoma, will take place on November 15, 2019, 1:30-2:30 pm ET and will feature a panel of experts includ...

PLEASE NOTE: this site is in its early stages of development and the underlying predictive model has not yet been finalized or undergone peer review. If you have questions or feedback, please email aard@uw.edu Disclaimer: No Medical Advice. ALTHOUGH SOME CONTENT MAY BE PROVIDED BY INDIVIDU...

Merkel cell carcinoma (MCC) is an aggressive skin cancer that recurs in more than one-third of cases, with reported mortality rates of 33%to 46%.1 Given this high risk situation, MCC is often managed with therapies that are aggressive and potentially toxic: extensive surgery, radiation therapy (RT),...

In October 2017, a multidisciplinary symposium on new developments in the comprehensive management of Merkel cell carcinoma was held at the University of Rochester Medical Center. The event included specialists across many disciplines such as dermatology, surgical oncology, otolaryngology, radiation...